Gatti, M.; Rinaldi, M.; Tonetti, T.; Siniscalchi, A.; Viale, P.; Pea, F.
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP. Antibiotics 2024, 13, 296.
https://doi.org/10.3390/antibiotics13040296
AMA Style
Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F.
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP. Antibiotics. 2024; 13(4):296.
https://doi.org/10.3390/antibiotics13040296
Chicago/Turabian Style
Gatti, Milo, Matteo Rinaldi, Tommaso Tonetti, Antonio Siniscalchi, Pierluigi Viale, and Federico Pea.
2024. "Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP" Antibiotics 13, no. 4: 296.
https://doi.org/10.3390/antibiotics13040296
APA Style
Gatti, M., Rinaldi, M., Tonetti, T., Siniscalchi, A., Viale, P., & Pea, F.
(2024). Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP. Antibiotics, 13(4), 296.
https://doi.org/10.3390/antibiotics13040296
